I. Solman

Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.

J. Byrd, U. Jaeger, T. Kipps, 2019, Clinical lymphoma, myeloma & leukemia.

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

L. Coussens, M. Tempero, C. Lopez, 2023, Journal for ImmunoTherapy of Cancer.

Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.

J. Byrd, T. Kipps, S. Mulligan, 2020, Leukemia research.

Title Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Schuh, Stephen, Jeffrey A Jones, 2019 .

Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jeffrey A Jones, J. Byrd, U. Jaeger, 2018, Clinical lymphoma, myeloma & leukemia.

Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.

T. Kipps, J. Burger, J. Dean, 2021, Leukemia research.

11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies

J. Byrd, U. Jaeger, T. Kipps, 2016 .